Ehave Provides Progress Update on its HPPD Study with University of Melbourne

• Post published:February 2, 2023
• Post category:Press Release

FDA Grants Ehave Consent to Proceed With Its Clinical Study on Intravenous Ketamine Infusion for Major Depressive Disorder

• Post published:December 15, 2022
• Post category:Press Release

Ehave Shareholder from CEO Ben Kaplan and Corporate Update

• Post published:December 7, 2022
• Post category:Press Release

Ehave, Inc. Announces its KetaDASH Mobile Unit will be Delivered to Miami Beach on June 10, 2022

• Post published:June 3, 2022
• Post category:Press Release

Ehave Forms Partnership with Cognitive Apps to Introduce Revolutionary AI Voice Assistant That Will Revolutionize Mental Health in Psychedelic Sector

• Post published:January 11, 2021
• Post category:Press Release

Ehave, Inc. Partners with Cognitive Apps to Add Artificial Intelligence-Powered Mental Health Analytical Platform for Psychedelic Use in G20 Countries

• Post published:January 7, 2021
• Post category:Press Release

Ehave, Inc. Files to List on the Canadian Stock Exchange and Applies to Upgrade to OTCQB Exchange

• Post published:January 4, 2021
• Post category:Press Release

Ehave, Inc. Announces Repositioning of Mycotopia Therapies to Maximize Shareholder Value

• Post published:December 28, 2020
• Post category:Press Release

Ehave KetaDASH Subsidiary Announces Intent to Battle Major Depression through Home Delivery of Ketamine

• Post published:December 23, 2020
• Post category:Press Release

Ehave, Inc. Issues CEO Letter to Stockholders, Reports on Significant Progress and Outlook for 2021

• Post published:December 17, 2020
• Post category:Press Release